 A Food and Drug Administration advisory committee is set to meet this week to discuss three cancer therapies. The Oncologic Drugs Advisory Committee is set to meet Wednesday to vote whether the benefits of Spectrum Pharmaceuticals Inc.s SPPI, -1.39 treatment of patients with certain types of non-small cell lung cancer outweigh the risks. 